Epigral Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/828mdu9b2cwkudgh1b7wtcxf.pdf

Key Takeaways


CPVC: The Star Performer

Maulik Patel: "We are very confident in terms of the chemistry and the confidence in the team. And it is -- we are increasing based on the demand in India right now, India needs more CPVC and we have an experience of last six months and looking at the future of demand of CPVC, we feel that it is right time to expand."

ECH: The Delayed Promise

Milind Kotecha: "It has been delayed by maybe six months or a year's time till the time demand again pickups."

Margin & Profitability Dynamics

Milind Kotecha: "Margins will not improve drastically from here on what we have achieved in the last nine months. It will be in the range of what we have communicated in terms of guidance, which is around 28%."

Demand Environment & Market Outlook

Maulik Patel: "If China internal demand improved, the global any industry will change the supply-demand scenario overnight, and I think the situation changed in terms of the pricing in the globally in terms of demand also."

Strategic Direction & Capital Allocation

Maulik Patel: "And our focus is very clear that, we would like to grow in the next three years in the derivative side of chlor-alkali... we are planning 50% revenue will come from chlor-alkali, 50% will come from value addition and the downstream industry."

Guidance & Commitments

CommitmentSpecificsTimeline
CPVC Phase 2 commissioningAdditional 45,000 TPA capacity onlineQ4 FY24
Chlorotoluene value chain commissioningFirst phase of 10–15 derivative products onlineQ4 FY24
ECH optimized utilizationReach optimized capacity utilizationQ1 FY24
Caustic soda expanded capacity utilizationReach optimum utilization of additional 1,06,000 TPAEnd of Q4 FY23
Revenue mix target50% chlor-alkali, 50% derivativesWithin two years
Internal chlorine consumption target~75% (from ~65% currently)Within two years
Long-term EBITDA margin28% plus-or-minus two percentage pointsOngoing
Volume growth expectation15% to 20% annually, capex-drivenAnnual
Revenue growth expectation25% to 30% year-on-yearAnnual

Key Metrics

MetricQ3 FY23
Revenue₹538 cr, +27% YoY
Volume growth18% YoY
EBITDA₹167 cr, +18% YoY
EBITDA margin31%, vs 32.9% in 9M FY23
PAT₹77 cr, +11% YoY
PAT margin14%, vs 17% in Q3 FY22
9M FY23 revenue₹1,626 cr, +55% YoY
9M FY23 PAT₹277 cr, +80% YoY
Return on capital employed35% (9M FY23)
Return on equity46% (9M FY23), vs 36% in FY22
Net debt to EBITDA1.3x, vs 2.4x in Q3 FY22
Chlor-Alkali capacity utilization68% on expanded capacities
Chloromethane capacity utilization104%
Hydrogen Peroxide capacity utilization82%
CPVC capacity utilization~40% quarterly average, reached 70% in December 2022
Derivatives & Specialty revenue share31% of revenue, vs 25% in Q3 FY22
Caustic soda ECU realization+2% YoY
Chloromethane sales realization-33% YoY
Hydrogen Peroxide sales realization+9%
Interim dividend₹2.5 per share, 25% on face value of ₹10